Nicotine lozenge (NRT)
Детермінований перегляд YAML-сутності з джерельної бази. Клінічний авторитет лишається за вказаними source ID та статусом клінічного sign-off.
| ID | DRUG-NICOTINE-LOZENGE |
|---|---|
| Тип | Препарат |
| Синоніми | CommitNRT lozengeNicorette LozengeNicotine lozengeNicotine mini-lozengeNicotine replacement therapy — lozengeNicotinell LozengeNiquitin MiniНікотинові льодяники (NRT) |
| Статус | переглянуто 2026-05-18 | очікує клінічного підпису |
| Хвороби | Не вказано |
| Джерела | SRC-IARC-100A-TOBACCO-SMOKING SRC-USPSTF-LUNG-LDCT-2021 |
Дані про препарат
| Клас | Nicotine replacement therapy (NRT) — buccal/sublingual short-acting |
|---|---|
| Механізм дії | Slowly dissolving lozenge releases nicotine across oral mucosa, producing a peak plasma level over ~20-30 minutes that blunts acute craving and withdrawal symptoms. Pharmacokinetics avoid the rapid arterial bolus that drives reinforcement from inhaled smoking. Cancer-prevention rationale: tobacco cessation reduces incidence of lung, head-and-neck, bladder, esophageal, pancreatic, cervical, kidney, AML, and other tobacco-attributable cancers (IARC Monograph 100E — Personal Habits and Indoor Combustions). NRT roughly doubles 6-month abstinence vs. placebo (Cochrane); combining a long-acting patch with a short-acting form (lozenge or gum) PRN improves quit rates over monotherapy. USPSTF Grade A for adult tobacco-cessation pharmacotherapy. |
| Типове дозування | Strength selection by time-to-first-cigarette (TTFC) of the day: - TTFC ≤30 min OR ≥20 cig/d: start 4 mg lozenge - TTFC >30 min OR <20 cig/d: start 2 mg lozenge Cadence (10-12 week course typical): - Weeks 1-6: 1 lozenge every 1-2 h (≥9 lozenges/day at start) - Weeks 7-9: 1 lozenge every 2-4 h - Weeks 10-12: 1 lozenge every 4-8 h Maximum 20 lozenges/day. Allow 20-30 min to dissolve; do NOT chew or swallow whole. Avoid food/drink (especially acidic — coffee, juice, soft drinks) for 15 minutes before/during use — acidic pH in mouth dramatically reduces buccal absorption. PRN dosing acceptable for breakthrough craving when used as add-on to patch. |
| Зареєстровано в Україні | True |
| Відшкодовується НСЗУ | False |
| Остання перевірка для України | 2026-05-18 |
Нотатки
STUB — v0.2 prevention-workstream authoring (batch 2); pending two- Clinical-Co-Lead signoff per CHARTER §6.1 dev-mode. NRT lozenge is a first-line tobacco-cessation pharmacotherapy (USPSTF Grade A for adults; insufficient evidence in pregnancy). PARTNER to DRUG-NICOTINE- PATCH (long-acting baseline) — combination patch + PRN lozenge or gum is preferred over either monotherapy (Cochrane Stead 2012). TOBACCO CESSATION is the highest-yield modifiable cancer-prevention intervention in adults — IARC class 1 for ≥17 cancer sites. Primary cessation RCTs (e.g., Shiffman 2002, West 2008) not yet ingested as standalone SRC-* entities; cited sources cover (a) the tobacco-cancer causal relationship (IARC-100A) and (b) the lung-cancer screening context where cessation is integrated (USPSTF-LUNG-LDCT-2021). Engine should surface cessation NRT options when prevention pilots flag current tobacco use; choice of patch vs lozenge vs gum vs varenicline vs bupropion belongs to the patient/clinician dialogue, not the algorithm.
Де використовується
Препарат
DRUG-NICOTINE-GUM- Nicotine gum (NRT)